Indicator Explainer
Sirolimus
A natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. This results in inhibition of T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (IL-2, IL-4, and IL-15) stimulation and inhibition of antibody production. (NCI04)
This page explains what the indicator is and how results are interpreted in general terms. Reference ranges depend on the laboratory, the method, and your own situation — no single “normal value” applies to everyone. This page is health information, not a diagnosis. For symptoms, treatment, or urgent concerns, contact a healthcare professional.
When it is tested
Source: National Cancer Institute, NCI Thesaurus 26.09d, C1212. NCI definition, reproduced without modification under CC BY 4.0. Source identity and definition checked automatically on 2026-10-20. No individual clinical interpretation or human reviewer is asserted.
Reading results
Reference intervals and interpretation depend on the laboratory, specimen, method and clinical context. This source definition is educational information; it does not establish a diagnosis, product approval or suitability for an individual.
Also Known As
References
- NCI Thesaurus 26.09d — Sirolimus (C1212)
- Source: National Cancer Institute, NCI Thesaurus 26.09d, C1212. NCI definition, reproduced without modification under CC BY 4.0.
- PTCy, sirolimus, MMF and RGI-2001 to explore regulatory T-cell expansion following haploidentical peripheral blood stem cell transplantation: a pilot study. — Leuk Lymphoma, 2026-10-20 (PMID 42897991; literature)
- Sirolimus-based immunosuppression and reported rejection or death in heart transplant recipients using the U.S. Food and Drug Administration Adverse Event Reporting System. — Clin Transplant Res, 2026-10-20 (PMID 42897907; literature)
- Biolimus- versus sirolimus-eluting stents in percutaneous coronary intervention: a comprehensive systematic review and meta-analysis of randomised controlled trials. — AsiaIntervention, 2026-10-23 (PMID 42923777; literature)
- Drug-coated balloons in coronary disease: meta-analysis comparing sirolimus- and paclitaxel-coated technologies. — BMC Cardiovasc Disord, 2026-10-22 (PMID 42919160; literature)
- Sirolimus and Immunoglobulin Replacement Therapy in Patients with Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS): A Systematic Literature Review. — Adv Ther, 2026-10-26 (PMID 42932134; literature)
- Beyond the cerebrospinal fluid: Preclinical and clinical evidence on central nervous system penetration and functional activity of oral rapamycin (sirolimus). — J Alzheimers Dis, 2026-10-09 (PMID 42852863; literature)